Q3 Earnings Forecast for LBRX Issued By Leerink Partnrs

Key Points

• Leerink Partners has projected LB Pharmaceuticals Inc (NASDAQ:LBRX) will report a Q3 2025 earnings per share of ($0.80), with future earnings expectations also indicating losses for upcoming fiscal years.
• The stock currently holds a consensus rating of "Buy" from analysts, with target prices ranging from $27.00 to $34.00.
• Director Ran Nussbaum significantly increased his stake in the company by purchasing 1,000,000 shares at an average price of $15.00, resulting in a 242.91% increase in ownership.

LB Pharmaceuticals Inc (NASDAQ:LBRX - Free Report) - Leerink Partnrs issued their Q3 2025 earnings per share estimates for LB Pharmaceuticals in a report issued on Monday, October 6th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings of ($0.80) per share for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. Leerink Partnrs also issued estimates for LB Pharmaceuticals' Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($3.30) EPS, FY2027 earnings at ($3.15) EPS, FY2028 earnings at ($3.10) EPS and FY2029 earnings at ($5.00) EPS.

Other equities research analysts have also issued research reports about the company. Leerink Partners initiated coverage on LB Pharmaceuticals in a research note on Monday. They set an "outperform" rating and a $34.00 price target on the stock. Wall Street Zen raised shares of LB Pharmaceuticals to a "hold" rating in a research report on Monday, September 22nd. Piper Sandler started coverage on LB Pharmaceuticals in a research note on Monday. They issued an "overweight" rating on the stock. Finally, Stifel Nicolaus started coverage on shares of LB Pharmaceuticals in a report on Monday. They issued a "buy" rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $30.50.

LB Pharmaceuticals Price Performance

LB Pharmaceuticals stock opened at $16.01 on Wednesday. LB Pharmaceuticals has a one year low of $13.36 and a one year high of $20.25.

Insider Buying and Selling at LB Pharmaceuticals

In other LB Pharmaceuticals news, Director Ran Nussbaum bought 1,000,000 shares of the company's stock in a transaction dated Friday, September 12th. The shares were acquired at an average cost of $15.00 per share, with a total value of $15,000,000.00. Following the completion of the transaction, the director owned 1,411,681 shares in the company, valued at $21,175,215. The trade was a 242.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

About LB Pharmaceuticals

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.